remifentanil has been researched along with Carcinoma, Hepatocellular in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ke, J; Liang, W | 1 |
| Chen, HX; He, Y; Hei, Z; Jian, C; Li, X; Pan, J; Zhou, S | 1 |
| Duan, WN; Jia, Q; Jia, YF; Tian, F; Wang, HX; Xia, ZY | 1 |
| Chen, MS; Huang, W; Li, W; Li, Y; Long, YH; Wang, J; Xu, MX | 1 |
3 trial(s) available for remifentanil and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Comparison of dexmedetomidine vs. remifentanil combined with sevoflurane during radiofrequency ablation of hepatocellular carcinoma: a randomized controlled trial.
Topics: Adult; Aged; Anesthesia, General; Carcinoma, Hepatocellular; Catheter Ablation; Dexmedetomidine; Female; Heart Rate; Humans; Liver Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Pain, Postoperative; Prospective Studies; Remifentanil; Sevoflurane | 2019 |
Effects of Dezocine-Remifentanil Intravenous Anaesthesia on Perioperative Signs, Serum TNF-&aipha; and IL-6 in Liver Cancer Patients undergoing Radiofrequency Ablation.
Topics: Adult; Aged; Analgesics, Opioid; Anesthesia, Intravenous; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Interleukin-6; Liver Neoplasms; Male; Middle Aged; Radiofrequency Ablation; Remifentanil; Tetrahydronaphthalenes; Treatment Outcome; Tumor Necrosis Factor-alpha | 2019 |
[Application of total intravenous anesthesia with remifentanyl and propofol to radiofrequency ablation].
Topics: Anesthesia Recovery Period; Anesthetics, Intravenous; Blood Pressure; Carbon Dioxide; Carcinoma, Hepatocellular; Catheter Ablation; Female; Fentanyl; Heart Rate; Humans; Infusions, Intravenous; Injections, Intravenous; Liver Neoplasms; Male; Middle Aged; Piperidines; Propofol; Remifentanil; Respiration | 2007 |
1 other study(ies) available for remifentanil and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Remifentanil reduces the proliferation, migration and invasion of HCC cells via lncRNA NBR2/miR-650/TIMP3 axis.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Neoplasm Invasiveness; Remifentanil; RNA, Long Noncoding; Tissue Inhibitor of Metalloproteinase-3 | 2022 |